Introduction:
Novocure (NVCR) is a mid-cap medical devices company which has a growing pipeline of clinical trials to treat cancer patients with its Tumor Treating Fields. Successful clinical trials in Glioblastoma have now led the treatment to be commercially available. The company is continuing its momentum with mesothelioma and has secured FDA approval for its TTF based treatment.
Novocure sold off from an all time high of $97.8 on Aug 21, 2019. The 20% drop in stock price was more or less anticipated by many long term investors. The much needed pullback